S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
HSTC
HST Global
$1.12
$0.69
$0.10
$1.15
N/A-1.06230 shs50 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$5.27
-3.1%
$4.48
$2.31
$7.15
$28.92M1.0561,479 shs11,278 shs
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
$0.13
$0.03
$0.38
$21.70MN/A52,703 shs198,200 shs
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
$2.06
$1.26
$4.26
$8.11M0.98162,968 shs2,579 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
HSTC
HST Global
0.00%0.00%+123.96%+214.85%+1,020.00%
Lipocine Inc. stock logo
LPCN
Lipocine
+2.26%-15.13%+27.70%+44.30%+4.92%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
0.00%0.00%0.00%0.00%0.00%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
HSTC
HST Global
N/AN/AN/AN/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/AN/AN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
HSTC
HST Global
N/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
HSTC
HST Global
N/AN/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
$-2.85M-9.83N/AN/A$3.83 per share1.38
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/A$0.01 per shareN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/A$2.48 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
HSTC
HST Global
-$150K-$0.04N/AN/AN/AN/A-9,797.01%N/A
Lipocine Inc. stock logo
LPCN
Lipocine
-$16.35M-$3.05N/AN/AN/A-63.28%-58.27%5/9/2024 (Estimated)
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
-$8.64MN/A0.00N/AN/AN/A-72.60%-55.68%N/A

Latest LPCN, HSTC, REXN, and PVOTF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/5/2024Q4 2023
HSTC
HST Global
N/A-$0.01-$0.01-$0.01N/AN/A
3/7/2024Q4 2023
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.53-$0.42+$0.11-$0.42N/A$0.22 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
HSTC
HST Global
N/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
HSTC
HST Global
N/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/A
8.69
8.69
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A
3.62
3.62
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/A
3.37
3.37

Ownership

Institutional Ownership

CompanyInstitutional Ownership
HSTC
HST Global
N/A
Lipocine Inc. stock logo
LPCN
Lipocine
9.11%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
7.49%

Insider Ownership

CompanyInsider Ownership
HSTC
HST Global
65.82%
Lipocine Inc. stock logo
LPCN
Lipocine
5.00%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
34.77%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
1.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
HSTC
HST Global
1N/AN/ANot Optionable
Lipocine Inc. stock logo
LPCN
Lipocine
175.32 million5.05 millionNo Data
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A171.41 millionN/ANot Optionable
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
54.48 millionN/AOptionable

LPCN, HSTC, REXN, and PVOTF Headlines

SourceHeadline
Aurinia Pharmaceuticals Inc AUPHAurinia Pharmaceuticals Inc AUPH
morningstar.com - February 16 at 5:49 PM
MaxCyte Appoints Douglas Swirsky as Chief Financial OfficerMaxCyte Appoints Douglas Swirsky as Chief Financial Officer
benzinga.com - March 27 at 6:16 PM
Rexahn: Holes Galore in Serdaxin DataRexahn: Holes Galore in Serdaxin Data
thestreet.com - January 1 at 6:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

HST Global

OTCMKTS:HSTC
HST Global, Inc., an integrated health and wellness biotechnology company, develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer in the United States and internationally. The company also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancers and other life-threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.
Lipocine logo

Lipocine

NASDAQ:LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
BetterLife Pharma logo

BetterLife Pharma

OTCMKTS:PVOTF
BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.
Rexahn Pharmaceuticals logo

Rexahn Pharmaceuticals

NASDAQ:REXN
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.